Ann: Appendix 4C - Quarter ended 31 December 2017, page-17

Have made this comment before (and admittedly sold out 6 months ago based on it) - the product is great in concept and effectiveness. HOWEVER they are trying to sell into an oncology market for post-treatment outcomes of patients who are unfortunately suffering known side-effects. The practitioners / Oncology centres aren't focused on the side-effects they are focused on saving lives. IPD needs to dramatically change their target audience or product uptake and sales will remain dormant. I remain in the wings until this occurs and simply wish Richard would wake up to why things aren't moving forward.